Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Valion Bio, Inc.

NASDAQ: VBIO · Life Sciences · 14 alerts · CIK 1787740

Share price
$0.5290Close, Nov 16
Market cap
$11.7M
Shares outstanding
22.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Valion Bio, Inc. filings on SEC EDGAR ↗

4:29 PM ET 8-K
Shareholder Meeting

Valion Bio Shareholder Meeting

Valion Bio held a special meeting of stockholders on November 12, 2026, where shareholders approved three key proposals. These included granting the board discretionary authority to effect a reverse stock split (ratio between 1-for-2 and 1-for-12) and amending the 2021 Equity Incentive Plan to increase the authorized share reserve by 272,000 shares.

6:04 AM ET 8-K
Capital Raise

Valion Bio Capital Raise of $700K

Valion Bio, Inc. completed a $700,000 closing under its existing Series B Preferred Purchase Agreement with 3i, LP, issuing 700 shares of Series B Non-Voting Convertible Preferred Stock and warrants to purchase 21,539 shares of common stock. As part of the agreement, the company committed to filing a registration statement for the resale of the underlying common shares within 30 days and extended the outside date for future closings to December 9, 2027.

Value
$700K
Counterparty
3i, LP
4:19 PM ET 8-K
Leadership Change

Valion Bio Leadership Change

Lisa Wolf has voluntarily resigned from her positions as President, Chief Operating Officer, and Chief Financial Officer of Valion Bio, Inc. Her resignation is scheduled to become effective on December 11, 2026.

7:50 AM ET 8-K
Leadership Change

Valion Bio Leadership Change

Valion Bio, Inc. terminated the employment of Melinda Lackey, General Counsel and Senior Vice President of Legal Affairs, effective October 30, 2026. Under a separation agreement, she will receive a lump-sum cash severance payment of $26,750 and temporary COBRA premium coverage.

7:46 AM ET 8-K
Clinical Trial Data

Valion Bio Clinical Trial Data

Valion Bio announced positive final safety data from a NIAID-funded study of its lead biologic candidate, Entolimod, conducted by the Armed Forces Radiobiology Research Institute (AFRRI). The study found no evidence of treatment-related toxicity or hematologic disruption in mice, supporting the advancement to a fully funded therapeutic study evaluating survival and gastrointestinal recovery following radiation exposure.

Counterparty
Armed Forces Radiobiology Research Institute
Term
14-day observation period
6:03 AM ET 8-K
Capital Raise

Valion Bio Capital Raise of $4.77M

Valion Bio, Inc. entered into side letters to issue Series B and Series C Preferred Shares and warrants for total proceeds of approximately $4.77 million. The transaction includes a $50,000 Series B closing with 3i, LP and a $4.72 million Series C closing with existing purchasers, part of which satisfies overdue cash true-up obligations.

Value
$4.77M
Counterparty
3i, LP
8:00 AM ET 8-K
M&A Deal

Valion Bio M&A Deal Update

Valion Bio has received unsolicited acquisition inquiries from third parties regarding its wholly owned CDMO subsidiary, Velocity Bioworks. The company has retained an investment bank to evaluate strategic options, including a potential sale, while prioritizing the retention of manufacturing rights for its lead drug candidate, Entolimod.

8:01 AM ET 8-K
Business Update

Valion Bio Business Update

Interim CEO Dean Zikria released a 30-day strategic assessment focusing on advancing the Entolimod clinical pipeline and commercializing the company's Velocity Bioworks CDMO unit. The company is exploring strategic partnerships and licensing deals to bridge the gap between its scientific assets and current market valuation.

8:00 AM ET 8-K
Business Update

Valion Bio Business Update

Valion Bio's subsidiary, Velocity Bioworks, successfully completed an initial feasibility evaluation of LarmorBio's BioScan-NMR platform, achieving a milestone in their partnership. The evaluation demonstrated that NMR measurements can track microbial growth in real-time, supporting the development of non-invasive bioprocess monitoring for biologics manufacturing.

Counterparty
LarmorBio, Inc.
8:15 AM ET 8-K
Business Update

Valion Bio Business Update

Valion Bio highlighted the capabilities of its wholly owned CDMO subsidiary, Velocity Bioworks, to support biotechnology companies seeking domestic U.S.-based manufacturing. The update follows the implementation of Section 232 pharmaceutical tariffs, positioning Velocity's San Antonio facility as a strategic option for early-phase clinical drug substance manufacturing.

6:04 AM ET 8-K
Capital Raise

Valion Bio Capital Raise

Valion Bio, Inc. entered into a letter agreement with 3i, LP to issue 50 shares of Series B Non-Voting Convertible Preferred Stock and warrants for 1,539 shares of common stock. The transaction resulted in gross proceeds of $50,000 as part of an ongoing securities purchase agreement. The warrants have an initial exercise price of $2.5520 per share.

Counterparty
3i, LP
7:45 AM ET 8-K
Leadership Change

Valion Bio Leadership Change

Valion Bio issued a press release highlighting the appointment and strategic goals of its new Board Chair, Thomas Jensen, who joined the board in September 2026. Jensen, the current CEO of Allarity Therapeutics, will focus on advancing the company's lead candidate, Entolimod, as a medical countermeasure for acute radiation syndrome. The company is leveraging Jensen's experience in biotech turnarounds to align strategic priorities with disciplined resource allocation.

7:46 AM ET 8-K
Business Update

Valion Bio Business Update

Valion Bio announced the successful completion of formulation work for a novel oral mucosal version of its radiation protection biologic, Entolimod, using Shear Kershman Laboratories' BioViscid platform. This milestone creates a potential needle-free delivery pathway that could significantly expand the addressable market for radiological emergency deployment. The company plans to move into studies testing systemic delivery into the bloodstream next.

Counterparty
Shear Kershman Laboratories
8:00 AM ET 8-K
Leadership Change

Valion Bio Leadership Change

Valion Bio, Inc. appointed Dean Zikria as Interim Chief Executive Officer, effective September 22, 2026, succeeding Sheryle Bolton who stepped down from the Board. Mr. Zikria, an existing director, will receive a monthly consulting fee of $23,333 and up to 100,000 restricted stock units as part of his interim leadership agreement.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.